Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Decoagulant Market by Type (Platelet aggregation inhibitors (PAI), Low-molecular-weight Heparin (LMWH), Direct thrombin inhibitor (DTI), Direct factor Xa inhibitors (DFXa), Vitamin K antagonists (VKA), Others), By Application (VTE, ACS/MI, AF, Others) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Decoagulant Market by Type (Platelet aggregation inhibitors (PAI), Low-molecular-weight Heparin (LMWH), Direct thrombin inhibitor (DTI), Direct factor Xa inhibitors (DFXa), Vitamin K antagonists (VKA), Others), By Application (VTE, ACS/MI, AF, Others) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 186302 3300 Pharma & Healthcare 377 234 Pages 4.6 (46)
                                          

The global decoagulant market is expected to grow at a CAGR of 4.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of thrombotic disorders and cardiovascular diseases, which are major causes for blood clotting. The platelet aggregation inhibitors segment accounted for the largest share in the global decoagulant market in 2018 and is expected to maintain its dominance throughout the forecast period. Platelet aggregation inhibitors (PAI) accounted for a significant share in the global decoagulant market in 2018 and are expected to maintain their dominance throughout the forecast period. PAIs inhibit platelets from aggregating together by blocking their receptors on cell surfaces, thereby preventing them from sticking together and forming clots that can block blood vessels or cause heart attacks or strokes. Lomoleculaweight Heparin (LMWH) was one of the most commonly used PAIs due to its long-lasting effect on inhibiting platelets from aggregating together with other cells, thereby reducing risk of bleeding complications associated with other types of PAIs such as heparinoids or low molecular weight heparins (LMWHs). Direct thrombin inhibitor (DTI) was another type that gained popularity due to its ability to inhibit clot formation by directly targeting thrombin molecules responsible for clot formation without affecting other coagulation factors such as fibrinogen or factor VIIa like LMWHs do. Direct factor Xa inhibitors (DFXa) were also gaining traction due their ability not only target factor X but also factor IIa which helps prevent excessive bleeding after surgery while vitamin K antagonists (VKA) were used primarily as an alternative treatment option when patients cannot take oral anticoagulants because they have gastrointestinal problems or are allergic/sensitive towards them.

  1. Increasing prevalence of cardiovascular diseases.
  2. Increasing number of people suffering from diabetes.
  3. Growing awareness about the benefits of a healthy lifestyle.
  4. Increase in the number of people suffering from obesity.
  5. Increase in the number of people suffering from high blood pressure.

Industry Growth Insights published a new data on “Decoagulant Market”. The research report is titled “Decoagulant Market research by Types (Platelet aggregation inhibitors (PAI), Low-molecular-weight Heparin (LMWH), Direct thrombin inhibitor (DTI), Direct factor Xa inhibitors (DFXa), Vitamin K antagonists (VKA), Others), By Applications (VTE, ACS/MI, AF, Others), By Players/Companies Sanofi, Bayer, Boehringer Ingelheim, Johnson & Johnson, Genentech (Roche), AstraZeneca, Bristol-Myers Squibb, Aspen, Lilly, Otsuka, Pfizer, Daiichi Sankyo, The Medicines Company”.

Scope Of The Report

Report Attributes

Report Details

Report Title

Decoagulant Market Research Report

By Type

Platelet aggregation inhibitors (PAI), Low-molecular-weight Heparin (LMWH), Direct thrombin inhibitor (DTI), Direct factor Xa inhibitors (DFXa), Vitamin K antagonists (VKA), Others

By Application

VTE, ACS/MI, AF, Others

By Companies

Sanofi, Bayer, Boehringer Ingelheim, Johnson & Johnson, Genentech (Roche), AstraZeneca, Bristol-Myers Squibb, Aspen, Lilly, Otsuka, Pfizer, Daiichi Sankyo, The Medicines Company

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

234

Number of Tables & Figures

164

Customization Available

Yes, the report can be customized as per your need.


Global Decoagulant Industry Outlook


Global Decoagulant Market Report Segments:

The global Decoagulant market is segmented on the basis of:

Types

Platelet aggregation inhibitors (PAI), Low-molecular-weight Heparin (LMWH), Direct thrombin inhibitor (DTI), Direct factor Xa inhibitors (DFXa), Vitamin K antagonists (VKA), Others

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

VTE, ACS/MI, AF, Others

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Sanofi
  2. Bayer
  3. Boehringer Ingelheim
  4. Johnson & Johnson
  5. Genentech (Roche)
  6. AstraZeneca
  7. Bristol-Myers Squibb
  8. Aspen
  9. Lilly
  10. Otsuka
  11. Pfizer
  12. Daiichi Sankyo
  13. The Medicines Company

Global Decoagulant Market Overview


Highlights of The Decoagulant Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Platelet aggregation inhibitors (PAI)
    2. Low-molecular-weight Heparin (LMWH)
    3. Direct thrombin inhibitor (DTI)
    4. Direct factor Xa inhibitors (DFXa)
    5. Vitamin K antagonists (VKA)
    6. Others
  1. By Application:

    1. VTE
    2. ACS/MI
    3. AF
    4. Others
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Decoagulant Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Decoagulant Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Decoagulant is a substance that helps to prevent blood from clotting.

Some of the major players in the decoagulant market are Sanofi, Bayer, Boehringer Ingelheim, Johnson & Johnson, Genentech (Roche), AstraZeneca, Bristol-Myers Squibb, Aspen, Lilly, Otsuka, Pfizer, Daiichi Sankyo, The Medicines Company.

The decoagulant market is expected to register a CAGR of 4.5%.

                                            
1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Decoagulant Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Decoagulant Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Decoagulant Market - Supply Chain
   4.5. Global Decoagulant Market Forecast
      4.5.1. Decoagulant Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Decoagulant Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Decoagulant Market Absolute $ Opportunity

5. Global Decoagulant Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Decoagulant Market Size and Volume Forecast by Type
      5.3.1. Platelet aggregation inhibitors (PAI)
      5.3.2. Low-molecular-weight Heparin (LMWH)
      5.3.3. Direct thrombin inhibitor (DTI)
      5.3.4. Direct factor Xa inhibitors (DFXa)
      5.3.5. Vitamin K antagonists (VKA)
      5.3.6. Others
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Decoagulant Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Decoagulant Market Size and Volume Forecast by Application
      6.3.1. VTE
      6.3.2. ACS/MI
      6.3.3. AF
      6.3.4. Others
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Decoagulant Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Decoagulant Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Decoagulant Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Decoagulant Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Decoagulant Demand Share Forecast, 2019-2026

9. North America Decoagulant Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Decoagulant Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Decoagulant Market Size and Volume Forecast by Application
      9.4.1. VTE
      9.4.2. ACS/MI
      9.4.3. AF
      9.4.4. Others
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Decoagulant Market Size and Volume Forecast by Type
      9.7.1. Platelet aggregation inhibitors (PAI)
      9.7.2. Low-molecular-weight Heparin (LMWH)
      9.7.3. Direct thrombin inhibitor (DTI)
      9.7.4. Direct factor Xa inhibitors (DFXa)
      9.7.5. Vitamin K antagonists (VKA)
      9.7.6. Others
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Decoagulant Demand Share Forecast, 2019-2026

10. Latin America Decoagulant Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Decoagulant Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Decoagulant Market Size and Volume Forecast by Application
      10.4.1. VTE
      10.4.2. ACS/MI
      10.4.3. AF
      10.4.4. Others
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Decoagulant Market Size and Volume Forecast by Type
      10.7.1. Platelet aggregation inhibitors (PAI)
      10.7.2. Low-molecular-weight Heparin (LMWH)
      10.7.3. Direct thrombin inhibitor (DTI)
      10.7.4. Direct factor Xa inhibitors (DFXa)
      10.7.5. Vitamin K antagonists (VKA)
      10.7.6. Others
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Decoagulant Demand Share Forecast, 2019-2026

11. Europe Decoagulant Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Decoagulant Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Decoagulant Market Size and Volume Forecast by Application
      11.4.1. VTE
      11.4.2. ACS/MI
      11.4.3. AF
      11.4.4. Others
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Decoagulant Market Size and Volume Forecast by Type
      11.7.1. Platelet aggregation inhibitors (PAI)
      11.7.2. Low-molecular-weight Heparin (LMWH)
      11.7.3. Direct thrombin inhibitor (DTI)
      11.7.4. Direct factor Xa inhibitors (DFXa)
      11.7.5. Vitamin K antagonists (VKA)
     11.7.6. Others
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Decoagulant Demand Share, 2019-2026

12. Asia Pacific Decoagulant Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Decoagulant Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Decoagulant Market Size and Volume Forecast by Application
      12.4.1. VTE
      12.4.2. ACS/MI
      12.4.3. AF
      12.4.4. Others
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Decoagulant Market Size and Volume Forecast by Type
      12.7.1. Platelet aggregation inhibitors (PAI)
      12.7.2. Low-molecular-weight Heparin (LMWH)
      12.7.3. Direct thrombin inhibitor (DTI)
      12.7.4. Direct factor Xa inhibitors (DFXa)
      12.7.5. Vitamin K antagonists (VKA)
      12.7.6. Others
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Decoagulant Demand Share, 2019-2026

13. Middle East & Africa Decoagulant Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Decoagulant Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Decoagulant Market Size and Volume Forecast by Application
      13.4.1. VTE
      13.4.2. ACS/MI
      13.4.3. AF
      13.4.4. Others
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Decoagulant Market Size and Volume Forecast by Type
      13.7.1. Platelet aggregation inhibitors (PAI)
      13.7.2. Low-molecular-weight Heparin (LMWH)
      13.7.3. Direct thrombin inhibitor (DTI)
      13.7.4. Direct factor Xa inhibitors (DFXa)
      13.7.5. Vitamin K antagonists (VKA)
      13.7.6. Others
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Decoagulant Demand Share, 2019-2026

14. Competition Landscape
   14.1. Global Decoagulant Market: Market Share Analysis
   14.2. Decoagulant Distributors and Customers
   14.3. Decoagulant Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Sanofi
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. Bayer
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. Boehringer Ingelheim
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. Johnson & Johnson
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. Genentech (Roche)
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. AstraZeneca
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. Bristol-Myers Squibb
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. Aspen
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. Lilly
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. Otsuka
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. Pfizer
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. Daiichi Sankyo
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. The Medicines Company
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. COMPANY 14
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. COMPANY 15
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. COMPANY 16
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. COMPANY 17
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. COMPANY 18
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19. COMPANY 19
         14.4.19.1. Overview
         14.4.19.2. Financials
         14.4.19.3. Developments
         14.4.19.4. Strategic Outlook
      14.4.20. COMPANY 20
         14.4.20.1. Overview
         14.4.20.2. Financials
         14.4.20.3. Developments
         14.4.20.4. Strategic Outlook

Our Trusted Clients

Contact Us